Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus

Modern Rheumatology

Volumn 24, Issue 1, 2014, Pages 78-85

  Shimada, Yuki ^a   Asanuma, Yu Funakubo ^a   Yokota, Kazuhiro ^a   Yoshida, Yoshihiro ^a   Kajiyama, Hiroshi ^a   Sato, Kojiro ^a   Akiyama, Yuji ^a   Mimura, Toshihide ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Disease activity; Inflammation; Pentraxin 3; Systemic lupus erythematosus

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; DOUBLE STRANDED DNA ANTIBODY; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3; PREDNISOLONE; SERUM ALBUMIN; SERUM AMYLOID P; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIBODY TITER; ARTICLE; B SCAN; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOALBUMINEMIA; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX;

EID: 84905035484     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.852837     Document Type: Article

References (30)

1. Cieślik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 2012;45:119-28.
2. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28:1-13.
3. Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2011;343:237-49.
4. Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:196-202.
5. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med. 2011;155:425-33.
6. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001;44:2841-50.
7. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in antifungal innate immune response. Nature. 2002;420:182-6.
8. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404-7.
9. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypic long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102: 636-41.
10. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22: 10-4.
11. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-Artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2307-15.
12. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cǒte R, et al. Traditional Framingham risk scores fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-7.
13. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med. 1999;340:115-26.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
16. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29: 288-91.
17. Simmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assesment Group (BILAG). Q J Med. 1988;69:927-37.
18. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus. 1999;8:632-7.
19. ACR AD HOC Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608.
20. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revised. J AmSoc Nephrol 2004;15: 241-50 (Erratum in: J Am Soc Nephrol. 2004;15:835-6).
21. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Sagara M, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161-7.
22. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47: 471-7.
23. Hollan I, Bottazzi B, Cuccovillo I, Forre OT, Mikkelsen K, Saatvedt K, et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res. 2010;62:378-85.
24. Kim J, Koh JK, Lee EY, Park JA, Kim HA, Lee EB, et al. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin Exp Rheum. 2009;27:773-8.
25. Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Tafatpanah H, Afshari JT, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus. 2011;20:1494-500.
26. Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol. 2008;26:814-9.
27. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19: 685-708.
28. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:2350-7.
29. Hanly JG, Urowitz MB, Su L, Gordon C, Clarke A, Bernatsky S, et al. Antoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1726-32.
30. Doni A, Mantovani G, Porta C, Tuckermann J, Reichardt HM, Kleiman A, et al. Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells. J Biol Chem. 2008;283:29983-92.